Welcome to our dedicated page for Galmed Pharmaceu SEC filings (Ticker: GLMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading Galmed Pharmaceuticals’ latest 10-K can feel like parsing a clinical journal—hundreds of pages on Aramchol trials, cash runway projections, and patent timelines. If you have ever wondered “Galmed Pharmaceuticals SEC filings explained simply” or hunted through footnotes for the next NASH milestone, you know the challenge.
Stock Titan solves that problem. Our AI-powered summaries highlight exactly where the Phase III Aramchol data sits, flag R&D expense trends, and decode risk factors—all as soon as each document hits EDGAR. Whether you need a Galmed Pharmaceuticals quarterly earnings report 10-Q filing or a sudden Galmed Pharmaceuticals 8-K material events explained, real-time alerts surface the key numbers and language investors track.
Every filing type is covered:
- 10-K / annual report—cash runway and pipeline outlook, now in a “Galmed Pharmaceuticals annual report 10-K simplified” format.
- 10-Q / quarterly earnings—trial spend and dilution risk, complete with “Galmed Pharmaceuticals earnings report filing analysis”.
- Form 4 insider trades—instant emails on “Galmed Pharmaceuticals Form 4 insider transactions real-time” so you can see when executives buy more shares ahead of readouts.
- Proxy statement—clear tables on “Galmed Pharmaceuticals proxy statement executive compensation” linked to clinical milestones.
Need practical use cases? Monitor “Galmed Pharmaceuticals executive stock transactions Form 4”, compare R&D burn across quarters, or assess dilution clauses before the next raise—all in one dashboard. Start understanding Galmed filings with AI clarity and make decisions faster than ever.
Etsy, Inc. (ETSY) has filed a Form 144 dated 24 Jul 2025 disclosing a proposed insider sale. CEO Josh Silverman intends to dispose of 140,000 common shares, to be brokered through UBS Financial Services. At the market price implied in the filing, the lot is valued at $9.1 million, equal to roughly 0.13% of the 104.28 million shares outstanding. The shares come from a same-day cash exercise of employee stock options and may be sold on or after 24 Jul 2025.
The notice also details Silverman’s recent activity: over the past three months he sold 195,998 shares across three transactions, generating $10.8 million in gross proceeds. Form 144 is only an advance notice—sales may or may not occur—but continued insider selling can create a modest overhang and may be read as a negative signal on near-term management outlook. No operational, earnings or guidance data accompany the filing.
FAQ
What is the current stock price of Galmed Pharmaceu (GLMD)?
What is the market cap of Galmed Pharmaceu (GLMD)?
What is the primary focus of Galmed Pharmaceuticals?
What therapeutic area does Aramchol target?
How does Aramchol differentiate itself within its competitive landscape?
What role do patents and intellectual property play in Galmed’s strategy?
In what ways is Galmed advancing its clinical research?
What are the main components of Galmed’s business model?
How does Galmed approach combination therapy?
